Puma Biotechnology, Inc. (PBYI) — 10-Q Filings
All 10-Q filings from Puma Biotechnology, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Puma Biotech's Q3 Net Income Plunges 56% on Royalty Revenue Drop
— Nov 6, 2025 Risk: high
Puma Biotechnology, Inc. reported a significant decrease in net income for the three months ended September 30, 2025, falling to $8.844 million from $20.317 mil -
Puma Biotech Q1 Loss Widens on Increased R&D
— May 8, 2025 Risk: medium
Puma Biotechnology, Inc. reported its first quarter results for the period ending March 31, 2025. The company's net loss for the three months ended March 31, 20 -
Puma Biotech Q3 2024: $760M Revenue, $49.1M Net Loss
— Nov 7, 2024 Risk: medium
Puma Biotechnology, Inc. reported its Q3 2024 results, with total revenues for the nine months ended September 30, 2024, reaching $760 million. The company's ne -
Puma Biotech's Nerlynx Sale Boosts Q2 Revenue to $250M
— Aug 1, 2024 Risk: medium
Puma Biotechnology, Inc. reported its Q2 2024 results for the period ending June 30, 2024. The company's net revenue for the three months ended June 30, 2024, w -
Puma Biotechnology, Inc. Files 10-Q for Period Ending March 31, 2024
— May 2, 2024 Risk: low
PUMA BIOTECHNOLOGY, INC. (PBYI) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Puma Biotechnology reported total revenue of $99.0 million for the
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX